Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.56 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 5/20 | 0.52 |
| ▸ | DRD4 | P21917 | 5/20 | 0.52 |
| ▸ | DRD3 | P35462 | 4/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8884316 | 0.86 | OPRM1 (0.78) | OPRM1CHRM1OPRK1OPRL1DRD2 | |
| SCHEMBL6504966 | 0.78 | OPRM1 (0.70) | OPRM1CHRM1OPRK1OPRL1DRD2 | |
| SCHEMBL6528091 | 0.77 | OPRM1 (0.66) | OPRM1CHRM1OPRK1OPRL1SMN1; SMN2 | |
| SCHEMBL6161133 | 0.77 | CHRM1 (0.92) | OPRM1CHRM1OPRK1OPRL1DRD2 | |
| SCHEMBL4930480 | 0.73 | SMN1; SMN2 (0.60) | OPRM1CHRM1OPRK1SMN1; SMN2PGR | |
| SCHEMBL11037100 | 0.73 | CHRM1 (0.52) | OPRM1CHRM1OPRK1SMN1; SMN2POLB | |
| SCHEMBL11507484 | 0.73 | DRD2 (0.86) | OPRM1CHRM1OPRK1DRD2DRD4 | |
| SCHEMBL3665096 | 0.72 | OPRM1 (1.00) | OPRM1CHRM1OPRK1OPRL1DRD2 | |
| SCHEMBL11179730 | 0.70 | OPRM1 (0.72) | OPRM1CHRM1OPRK1OPRL1DRD2 | |
| SCHEMBL7634043 | 0.70 | OPRM1 (0.87) | OPRM1CHRM1OPRK1OPRL1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1810677-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2007-07-25 | — | — | EP | disclosed |
| EP-1810677-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021069-A1 | Receptor Function Regulating Agent | GPR119, INSR, GPR65 | OPRM1 626/4885CHRM1 1348/4885OPRK1 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.